Analysts think INDP stock price could increase by 1934%
Jun 09, 2025, 11:25 AM
0.00%
What does INDP do
Indaptus Therapeutics, a preclinical biotechnology company based in New York City, focuses on multi-targeted immune system activation using a Decoy platform for anti-tumor and anti-viral responses. Its lead candidate, Decoy20, shows promise against chronic HBV and HIV infections.
4 analysts think INDP stock price will increase by 1934.19%. The current median analyst target is $7.14 compared to a current stock price of $0.35. The lowest analysts target is $2.02 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.